Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

EPT Disclosure

30 Mar 2010 12:48

RNS Number : 4246J
Piper Jaffray Ltd
30 March 2010
 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS

WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RI STATUS

BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

(Rule 38.5(b) of the Takeover Code)

 

 

1. KEY INFORMATION

 

Name of exempt principal trader

Piper Jaffray Ltd.

Company dealt in

Ark Therapeutics Group plc 

Class of relevant security to which the dealings being disclosed relate (Note 1)

Ord 1p

Date of dealing

29 March 2010

 

 

2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)

 

 

 

Long

Short

 

 

Number (%)

Number (%)

(1) Relevant securities

 

230,196 0.11%

(2) Derivatives (other than options)

 

(3) Options and agreements to purchase/sell

 

Total

 

230,196 0.11%

 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)

 

Class of relevant security:

 

Long

Short

 

 

Number (%)

Number (%)

(1) Relevant securities

 

(2) Derivatives (other than options)

 

(3) Options and agreements to purchase/sell

 

Total

 

 

(c) Rights to subscribe (Note 2)

 

Class of relevant security:

 

Details

 

 

3. DEALINGS (Note 3)

 

(a) Purchases and sales

 

Purchase/sale

 

Number of securities

Price per unit (Note 4)

Buy

10,000

11.00p

Buy

10,000

11.25p

 

 

(b) Derivatives transactions (other than options)

 

Product name,

e.g. CFD

Long/short (Note 5)

Number of securities (Note 6)

Price per unit (Note 4)

 

 

 

 

 

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

 

Product name,

e.g. call option

 

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 6)

Exercise

price

Type, e.g. American, European etc.

Expiry

date

Option money

paid/received per unit (Note 4)

 

 

(ii) Exercising

 

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 4)

 

 

 

 

(d) Other dealings (including new securities) (Note 3)

 

Nature of transaction (Note 7)

 

Details

Price per unit (if applicable) (Note 4)

 

 

 

 

4. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

Is a Supplemental Form 38.5(b) attached? (Note 8) NO

 

 

Date of disclosure

30 March 2010

Contact name

Norman Gould

Telephone number

020 3142 8780

Name of offeree/offeror with which connected

Ark Therapeutics Group plc 

Nature of connection (Note 9)

Adviser and broker

 

 

Notes

 

The Notes on Form 38.5(b) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
EMMURSARRNAOOAR
Date   Source Headline
2nd Jun 20154:55 pmRNSChange of Auditor
29th May 20157:00 amRNSHalf Yearly Report
7th May 20153:42 pmRNSChange of Registered Office
29th Apr 20157:01 amRNSTrading Statement
29th Apr 20157:00 amRNSFinal Results
13th Mar 201511:22 amRNSHolding(s) in Company
9th Mar 20157:00 amRNSRenamed Premier Veterinary Group
3rd Mar 201512:33 pmRNSHolding(s) in Company
3rd Mar 20159:48 amRNSHolding(s) in Company
2nd Mar 20152:36 pmRNSHolding(s) in Company
2nd Mar 201510:55 amRNSHolding(s) in Company
2nd Mar 201510:42 amRNSHolding(s) in Company
27th Feb 20154:35 pmRNSPrice Monitoring Extension
27th Feb 20154:07 pmRNSBoard Changes and Directors' Dealings
27th Feb 20158:00 amRNSCancellation
27th Feb 20157:00 amRNSAdmission to the Official List
26th Feb 20154:00 pmRNSCancellation and Publication of Prospectus
5th Feb 20154:22 pmRNSAcquisition completed
28th Jan 20159:29 amRNSSale and Purchase Agreement Signed
15th Jan 20157:00 amRNSTransfer of listing category on the Official List
4th Dec 201411:17 amRNSBlocklisting Interim Review
21st Nov 20145:48 pmRNSPosting of Circular
1st Aug 20147:00 amRNSHalf Yearly Report and Change of Registered Office
1st Jul 20147:00 amRNSResults of AGM and Board Changes
3rd Jun 20147:00 amRNSBlocklisting Interim Review
13th May 20147:00 amRNSInterim Management Statement
30th Apr 20147:00 amRNSFinal Results
28th Mar 20147:45 amRNSSuspension - Ark Therapeutics Group Plc
28th Mar 20147:32 amRNSSigned Heads of Terms and Suspension of Trading
25th Mar 201412:48 pmRNSHolding(s) in Company
4th Mar 201412:22 pmRNSHolding(s) in Company
21st Feb 20144:40 pmRNSSecond Price Monitoring Extn
21st Feb 20144:35 pmRNSPrice Monitoring Extension
20th Feb 201410:44 amRNSHolding(s) in Company
20th Feb 201410:39 amRNSHolding(s) in Company
20th Feb 201410:38 amRNSHolding(s) in Company
6th Dec 20135:46 pmRNSBlocklisting Interim Review
6th Nov 20137:00 amRNSInterim Management Statement
8th Oct 201311:27 amRNSHolding(s) in Company
7th Oct 20134:35 pmRNSPrice Monitoring Extension
7th Oct 20133:21 pmRNSHolding(s) in Company
27th Sep 201311:46 amRNSHolding(s) in Company
26th Sep 20133:26 pmRNSHolding(s) in Company
24th Sep 201311:02 amRNSHolding(s) in Company
20th Sep 201311:47 amRNSHolding(s) in Company
18th Sep 20134:40 pmRNSSecond Price Monitoring Extn
18th Sep 20134:35 pmRNSPrice Monitoring Extension
17th Sep 201310:00 amRNSHolding(s) in Company
13th Sep 201311:40 amRNSHolding(s) in Company
10th Sep 201310:37 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.